BMY - Illumina announces strategic partnership with BMY KURA MYGN and Merck to advance comprehensive genomic profiling; provides 2021 guidance

Illumina ([[ILMN]] -1.7%) announces a portfolio of strategic  partnerships that aim to expand the reach of its powerhouse comprehensive genomic profiling family of products, TruSight™ Oncology.Myriad Genetics ([[MYGN]] +5.5%) to create a kit-based version of the myChoice companion diagnostic (or CDx) test for international markets for the company.Company's partnership with Kura Oncology ([[KURA]] -5.1%) is focused on building a CDx claim for HRAS mutations in Head and Neck Squamous Cell Carcinomas.Expanding on a collaboration that began in 2018, Bristol Myers Squibb ([[BMY]] +3.8%) will develop a microsatellite instability CDx, as well as develop a diagnostic based on the content of TruSight Oncology 500 ctDNA, Illumina’s first liquid biopsy assay. Both program expansions are planned for global use by Bristol Myers Squibb’s portfolio of cancer therapeutics.Additionally, Illumina and Merck are conducting a study focused on the expanded TruSight Oncology HRD offering.“Increasing access to our products and better serving patients and healthcare providers are critical components of

For further details see:

Illumina announces strategic partnership with BMY, KURA, MYGN and Merck to advance comprehensive genomic profiling; provides 2021 guidance